miércoles, 27 de febrero de 2019

BMC Cancer | Experimental therapeutics and drug development

BMC Cancer | Experimental therapeutics and drug development

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.
Page 1 of 10
  1. Content Type:Research Article

    MicroRNAs are noncoding RNA molecules of ~ 22 nucleotides with diagnostic and therapeutic action [Curr Drug Targets, 2015. 16(12): p. 1381-403], affecting the expression of mRNAs involved in invasion, migratio...
    Authors:Olga D’Almeida, Omar Mothar, Esther Apraku Bondzie, Yolande Lieumo, Laure Tagne, Sumeet Gupta, Thomas Volkert, Stuart Levine and Jean-Bosco Tagne
    Citation:BMC Cancer 2019 19:136
    Published on: 
  2. Content Type:Research Article

    Treatment with recombinant human granulocyte-colony stimulating factor (G-CSF) is accepted standard for prevention of chemotherapy-induced neutropenia. RGB-02 (Gedeon Richter) is a proposed biosimilar to pegyl...
    Authors:Zsuzsanna Kahan, Daniela Grecea, Martin Smakal, Sergei Tjulandin, Igor Bondarenko, Luca Perjesi, Andras Illes, Karoly Horvat-Karajz and Ildiko Aradi
    Citation:BMC Cancer 2019 19:122
    Published on: 
  3. Content Type:Research Article

    Due to the lack of effective therapies and poor prognosis in TNBC (triple-negative breast cancer) patients, there is a strong need to develop effective novel targeted therapies for this subtype of breast cance...
    Authors:Nuramalina H. Mumin, Neele Drobnitzky, Agata Patel, Luiza Madia Lourenco, Fiona F. Cahill, Yanyan Jiang, Anthony Kong and Anderson J. Ryan
    Citation:BMC Cancer 2019 19:102
    Published on: 
  4. Content Type:Research Article

    Synthetic indolyl- pyridinyl- propenones (IPPs) induce methuosis, a form of non-apoptotic cell death, in glioblastoma and other cancer cell lines. Methuosis is characterized by accumulation of cytoplasmic vacu...
    Authors:Zehui Li, Nneka E. Mbah, Jean H. Overmeyer, Jeffrey G. Sarver, Sage George, Christopher J. Trabbic, Paul W. Erhardt and William A. Maltese
    Citation:BMC Cancer 2019 19:77
    Published on: 
  5. Content Type:Research Article

    To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeuti...
    Authors:Markus Moehler, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns and Thomas Thomaidis
    Citation:BMC Cancer 2019 19:55
    Published on: 
  6. Content Type:Research Article

    Shikonin, a natural naphthoquinone, is abundant in Chinese herb medicine Zicao (purple gromwell) and has a wide range of biological activities, especially for cancer. Shikonin and its analogues have been repor...
    Authors:Shoude Zhang, Qiang Gao, Wei Li, Luwei Zhu, Qianhan Shang, Shuo Feng, Junmei Jia, Qiangqiang Jia, Shuo Shen and Zhanhai Su
    Citation:BMC Cancer 2019 19:20
    Published on: 
  7. Content Type:Research Article

    A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysi...
    Authors:Yoshihiko Tomita, Hirotsugu Uemura, Mototsugu Oya, Nobuo Shinohara, Tomonori Habuchi, Yosuke Fujii, Yoichi Kamei, Yoshiko Umeyama, Angel H. Bair and Brian I. Rini
    Citation:BMC Cancer 2019 19:17
    Published on: 
  8. Content Type:Research Article

    Dung beetle glycosaminoglycan is known to possess anti-aging activities. However, its anti-cancer mechanisms are not fully elucidated yet. The objective of this study was to evaluate the anti-cancer effect of ...
    Authors:Mi Young Ahn, Ban Ji Kim, Ha Jeong Kim, Jang Mi Jin, Hyung Joo Yoon, Jae Sam Hwang and Kun-Koo Park
    Citation:BMC Cancer 2019 19:9
    Published on: 
  9. Content Type:Research Article

    The GTPase KRas4B has been utilized as a principal target in the development of anticancer drugs. PDE6δ transports KRas4B to the plasma membrane, where it is released to activate various signaling pathways req...
    Authors:Diana Casique-Aguirre, Paola Briseño-Díaz, Ponciano García-Gutiérrez, Claudia Haydée González-de la Rosa, Reyna Sara Quintero-Barceinas, Arturo Rojo-Domínguez, Irene Vergara, Luis Alberto Medina, José Correa-Basurto, Martiniano Bello, Rosaura Hernández-Rivas, María del RocioThompson-Bonilla and Miguel Vargas
    Citation:BMC Cancer 2018 18:1299
    Published on: 
  10. Content Type:Research Article

    HDIL-2 is approved for advanced melanoma based on its durable antitumor activity. MAGE-A3 cancer immunotherapeutic (MAGE-A3 CI) is a recombinant MAGE-A3 protein combined with an immunostimulant adjuvant system...
    Authors:Jennifer L. McQuade, Jade Homsi, Carlos A. Torres-Cabala, Roland Bassett, Rashmi Murthy Popuri, Marihella L. James, Luis M. Vence and Wen-Jen Hwu
    Citation:BMC Cancer 2018 18:1274
    Published on: 
  11. Content Type:Research Article

    Brain tumor vasculature can be significantly compromised and leakier than that of normal brain blood vessels. Little is known if there are vascular permeability alterations in the brain adjacent to tumor (BAT)...
    Authors:Afroz S. Mohammad, Chris E. Adkins, Neal Shah, Rawaa Aljammal, Jessica I. G. Griffith, Rachel M. Tallman, Katherine L. Jarrell and Paul R. Lockman
    Citation:BMC Cancer 2018 18:1225
    Published on: 
  12. Content Type:Research Article

    In case of high grade non-muscle invasive bladder cancer (HG-NMIBC), intravesical BCG represents the first-line treatment; despite the “gold” standard therapy, up to 50% of patients relapse, needing radical cy...
    Authors:Marco Racioppi, Luca Di Gianfrancesco, Mauro Ragonese, Giuseppe Palermo, Emilio Sacco and Pier Francesco Bassi
    Citation:BMC Cancer 2018 18:1224
    Published on: 
  13. Content Type:Research Article

    Agarose encapsulated murine renal adenocarcinoma cells (RENCA macrobeads) are currently being investigated in clinical trials as a treatment for therapy-resistant metastatic colorectal cancer. We have previous...
    Authors:Prithy C. Martis, Atira T. Dudley, Melissa A. Bemrose, Hunter L. Gazda, Barry H. Smith and Lawrence S. Gazda
    Citation:BMC Cancer 2018 18:1217
    Published on: 
  14. Content Type:Research Article

    Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity of G...
    Authors:Li Li, Yulun Huang, Yuge Gao, Tengfei Shi, Yunyun Xu, Huini Li, Marko Hyytiäinen, Jorma Keski-Oja, Qiuying Jiang, Yizhou Hu and Zhimin Du
    Citation:BMC Cancer 2018 18:1215
    Published on: 
  15. Content Type:Research Article

    The nudix family member enzyme MutT homologue-1 (MTH1) hydrolyses the oxidized nucleotides 8-oxo-dGTP and 2-hydroxy-dATP and thus prevents the incorporation of damaged nucleotides into nuclear and mitochondria...
    Authors:Mosche Pompsch, Julia Vogel, Fabian Classen, Philip Kranz, George Iliakis, Helena Riffkin, Ulf Brockmeier and Eric Metzen
    Citation:BMC Cancer 2018 18:1190
    Published on: 
  16. Content Type:Research Article

    Waixenicin A, a bioactive extract of soft coral Sarcothelia edmondsoni, has been shown to be anti-neoplastic. However, its mechanisms of action remain unclear. Cancer stem cells (CSCs) and associated stemness fac...
    Authors:Kai Liu, Shao-Hua Xu, Zhao Chen, Qing-Xin Zeng, Zhi-Jun Li and Zhou-Miao Chen
    Citation:BMC Cancer 2018 18:1167
    Published on: 
  17. Content Type:Research Article

    Insulin resistance (IR) is closely associated with the progression of hepatocellular carcinoma (HCC). Acyclic retinoid (ACR) targets retinoid X receptor α and reportedly prevents HCC recurrence in clinical pra...
    Authors:Norihisa Nishimura, Kosuke Kaji, Mitsuteru Kitade, Yosuke Aihara, Shinya Sato, Kenichiro Seki, Yasuhiko Sawada, Hiroaki Takaya, Yasushi Okura, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Akira Mitoro and Hitoshi Yoshiji
    Citation:BMC Cancer 2018 18:1164
    Published on: 
  18. Content Type:Case Report

    Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantat...
    Authors:Shupeng Wen, Zhiyun Niu, Lina Xing, Ying Wang, Hang Li, Na Kuang, Jianmin Luo, Xuejun Zhang and Fuxu Wang
    Citation:BMC Cancer 2018 18:1143
    Published on: 
  19. Content Type:Research Article

    Interactions between the protein synthesis inhibitor homoharringtonine (HHT) and the proteasome inhibitor bortezomib were investigated in DLBCL and mantle cell lymphoma cells (MCL).
    Authors:Tri Nguyen, Rebecca Parker, Yu Zhang, Elisa Hawkins, Maciej Kmieciak, William Craun and Steven Grant
    Citation:BMC Cancer 2018 18:1129
    Published on: 
  20. Content Type:Research Article

    The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neut...
    Authors:Henri Roché, Jean-Christophe Eymard, Abderraouf Radji, Alain Prevost, Rafik Diab, Michele Lamuraglia, Ravaka-Fatoma Soumoudronga, Isabelle Gasnereau and Alain Toledano
    Citation:BMC Cancer 2018 18:1127
    Published on: 
  21. Content Type:Case Report

    Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape o...
    Authors:Luca Bertamini, Jacopo Nanni, Giovanni Marconi, Mariachiara Abbenante, Valentina Robustelli, Francesco Bacci, Antonella Matti, Stefania Paolini, Chiara Sartor, Silvia Lo Monaco, Maria Chiara Fontana, Stefano De Polo, Michele Cavo, Antonio Curti, Giovanni Martinelli and Cristina Papayannidis
    Citation:BMC Cancer 2018 18:1117
    Published on: 
  22. Content Type:Research Article

    To identify potential therapeutic target in clear cell renal cell carcinoma (ccRCC), we performed a transcriptome analysis. Our analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean di...
    Authors:Kazuhiro Nagao, Nachi Shinohara, Frank Smit, Mirjam de Weijert, Sander Jannink, Yuji Owada, Peter Mulders, Egbert Oosterwijk and Hideyasu Matsuyama
    Citation:BMC Cancer 2018 18:1114
    Published on: 
  23. Content Type:Research Article

    Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-ca...
    Authors:Leila Kaeid Sharaf, Mridul Sharma, Deepika Chandel and Geeta Shukla
    Citation:BMC Cancer 2018 18:1111
    Published on: 
  24. Content Type:Case Report

    Cholangiocarcinoma, or bile duct cancer, is a gastrointestinal cancer with limited therapeutic options and a poor outcome. Studies have revealed that some major driver genes are associated with cholangiocarcin...
    Authors:Haibo Mou, Lanfang Yu, Qin Liao, Xuehua Hou, Yinfang Wu, Qiang Cui, Na Yan, Ruobing Ma, Lingjian Wang, Ming Yao and Kai Wang
    Citation:BMC Cancer 2018 18:1105
    Published on: 
  25. Content Type:Research Article

    In acute lymphoblastic leukemia (ALL), the presence of minimal residual disease (MRD) after induction/consolidation chemotherapy is a strong prognostic factor for subsequent relapse and mortality. Accordingly,...
    Authors:Arnaud Pigneux, Pau Montesinos, Ze Cong, Xinke Zhang, Anja K. Pownell, Heather Wieffer, Jan McKendrick and Monika Brüggemann
    Citation:BMC Cancer 2018 18:1100
    Published on: 
  26. Content Type:Research Article

    Colorectal cancer is the third most common cancer worldwide; and in 40% of all cases, KRAS4b-activating mutations occur. KRAS4b is transported by phosphodiesterase-6δ (PDEδ) to the plasma membrane, where it ge...
    Authors:Pedro Cruz-Nova, Michael Schnoor, José Correa-Basurto, Martiniano Bello, Paola Briseño-Diaz, Arturo Rojo-Domínguez, Carlos M. Ortiz-Mendoza, Jorge Guerrero-Aguirre, Francisco J. García-Vázquez, Rosaura Hernández-Rivas, María del Rocío Thompson-Bonilla and Miguel Vargas
    Citation:BMC Cancer 2018 18:1056
    Published on: 
  27. Content Type:Research Article

    Docosahexaenoic acid (DHA) is a long chain n-3 polyunsaturated fatty acid that has anticancer activity. Heme oxygenase 1 (HO-1) is a potential therapeutic target due to its cytoprotective activity in cancer ce...
    Authors:Yang Jiao, Tanya Watts, Jing Xue, Bethany Hannafon and Wei-Qun Ding
    Citation:BMC Cancer 2018 18:1042
    Published on: 
  28. Content Type:Research Article

    The chemotherapy resistance and toxicity of chemotherapy are major problems in breast cancer treatment. However, candidate biomarkers for predicting clinical outcomes and better prognosis remain lacking.
    Authors:Lu Chen, Huijie Qi, Liudi Zhang, Haixia Li, Jie Shao, Haifei Chen, Mingkang Zhong, Xiaojin Shi, Ting Ye and Qunyi Li
    Citation:BMC Cancer 2018 18:1038
    Published on: 
  29. Content Type:Research Article

    The RAS/RAF/MEK/ERK pathway is one of the most downregulated pathway in cancer. Inhibitors of RAF and MEK have established clinical use while ERK inhibitors recently faced the clinic. We aimed to generate resi...
    Authors:Alice Iezzi, Elisa Caiola, Arianna Scagliotti and Massimo Broggini
    Citation:BMC Cancer 2018 18:1028
    Published on: 
  30. Content Type:Research Article

    The Insulin-like growth factor (IGF) pathway plays a role in tumour development and progression. In vivo, IGF1 activity is regulated by the IGF binding proteins (IGFBPs). IGFBP4 inhibits the activity of IGF1 b...
    Authors:Y. E. Smith, S. Toomey, S. Napoletano, G. Kirwan, C. Schadow, A. J. Chubb, J. H. Mikkelsen, C. Oxvig and J. H. Harmey
    Citation:BMC Cancer 2018 18:1016
    Published on: 
  31. Content Type:Research Article

    Rigors are a significant adverse event during interleukin-2 (IL2) therapy for metastatic melanoma and renal cell carcinoma. Meperidine has been a mainstay for rigor prophylaxis but there is a paucity of data r...
    Authors:Brian Khong, Benjamin O. Lawson, Junjie Ma, Cheryl McGovern, Joan K. Van Atta, Abhijit Ray and Hung T. Khong
    Citation:BMC Cancer 2018 18:1007
    Published on: 
  32. Content Type:Research Article

    Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Neve...
    Authors:Roland Christian Schelker, Wolfgang Herr, Albrecht Reichle and Martin Vogelhuber
    Citation:BMC Cancer 2018 18:1000
    Published on: 
  33. Content Type:Research Article

    The tumour microenvironment conferred by mesenchymal stem cells (MSCs) plays a key role in tumour development and progression. We previously determined that platelet-activating factor receptor (PAFR) was overe...
    Authors:Tong Gao, Yi Yu, Qing Cong, Yisheng Wang, Mingming Sun, Liangqing Yao, Congjian Xu and Wei Jiang
    Citation:BMC Cancer 2018 18:999
    Published on: 
  34. Content Type:Research Article

    Conventional chemotherapy is commonly used to treat non-small cell lung cancer (NSCLC) however it increases therapeutic resistance. In contrast, metronomic chemotherapy (MET) is based on frequent drug administ...
    Authors:Rong-Sheng Qin, Zhen-Hua Zhang, Neng-Ping Zhu, Fei Chen, Qian Guo, Hao-Wen Hu, Shao-Zhi Fu, Shan-Shan Liu, Yue Chen, Juan Fan and Yun-Wei Han
    Citation:BMC Cancer 2018 18:967
    Published on: 
  35. Content Type:Study Protocol

    Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1–3 or 1–5 metastases in number. Stereotactic ablative radiothera...
    Authors:Robert Olson, Mitchell Liu, Alanah Bergman, Sonya Lam, Fred Hsu, Benjamin Mou, Tanya Berrang, Ante Mestrovic, Nick Chng, Derek Hyde, Quinn Matthews, Chad Lund, Daniel Glick, Howard Pai, Parminder Basran, Hannah Carolan…
    Citation:BMC Cancer 2018 18:954
    Published on: 
  36. Content Type:Research Article

    Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer. Besides their anti-tumour efficacy, several PKIs have also...
    Authors:Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli and Jürgen Grünberg
    Citation:BMC Cancer 2018 18:922
    Published on: 
  37. Content Type:Study Protocol

    Soft tissue sarcomas are a heterogeneous and rare group of solid tumors of mesenchymal origin that can arise anywhere in the body. Although surgical resection is the mainstay of treatment for patients with loc...
    Authors:Emily Z. Keung, Alexander J. Lazar, Keila E. Torres, Wei-Lien Wang, Janice N. Cormier, B. Ashleigh Guadagnolo, Andrew J. Bishop, Heather Lin, Kelly K. Hunt, Justin Bird, Valerae O. Lewis, Shreyaskumar R. Patel, Jennifer A. Wargo, Neeta Somaiah and Christina L. Roland
    Citation:BMC Cancer 2018 18:913
    Published on: 
  38. Content Type:Research Article

    There is an urgent need for more novel and efficacious therapeutic agents and strategies for the treatment of ovarian cancer - one of the most formidable female malignancies. These approaches should be based o...
    Authors:Vsevolod I. Kiselev, Levon A. Ashrafyan, Ekaterina L. Muyzhnek, Evgeniya V. Gerfanova, Irina B. Antonova, Olga I. Aleshikova and Fazlul H. Sarkar
    Citation:BMC Cancer 2018 18:904
    Published on: 
  39. Content Type:Research Article

    Although our previous study revealed lumbar punctured resveratrol could remarkably prolong the survival of rats bearing orthotopic glioblastomas, it also suggested the administration did not completely suppres...
    Authors:Xue Song, Xiao-Hong Shu, Mo-Li Wu, Xu Zheng, Bin Jia, Qing-You Kong, Jia Liu and Hong Li
    Citation:BMC Cancer 2018 18:871
    Published on: 
  40. Content Type:Research Article

    Melanoma is one of the most invasive and aggressive types of cancer with a very poor prognosis. Surgery remains the most efficient treatment prior melanoma invasion and metastasis formation. However, therapy b...
    Authors:Myra O. Villareal, Yuki Sato, Kyoko Matsuyama and Hiroko Isoda
    Citation:BMC Cancer 2018 18:856
    Published on: 
    The Correction to this article has been published in BMC Cancer 2018 18:902
  41. Content Type:Research Article

    Pleomorphic liposarcoma (PLPS) is a rare, heterogeneous and an aggressive variant of liposarcoma. Therefore, individualized therapy is urgently needed. Our recent reports suggest that trabectedin (TRAB) is eff...
    Authors:Tasuku Kiyuna, Yasunori Tome, Takashi Murakami, Kei Kawaguchi, Kentaro Igarashi, Kentaro Miyake, Masuyo Miyake, Yunfeng Li, Scott D. Nelson, Sarah M. Dry, Arun S. Singh, Tara A. Russell, Irmina Elliott, Shree Ram Singh, Fuminori Kanaya, Fritz C. Eilber…
    Citation:BMC Cancer 2018 18:840
    Published on: 
  42. Content Type:Research Article

    Colorectal cancer (CRC) remains a leading cause of death worldwide. Utilizing cisplatin in CRC is correlated with severe adverse effects and drug-resistance. Combined anticancer drug-treatment, along with, the...
    Authors:Mona M. Saber, Abdulaziz M. Al-mahallawi, Noha N. Nassar, Björn Stork and Samia A. Shouman
    Citation:BMC Cancer 2018 18:822
    Published on: 
  43. Content Type:Research Article

    The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan.
    Authors:Diego Tosi, Esther Pérez-Gracia, Salima Atis, Nadia Vié, Eve Combès, Mélissa Gabanou, Christel Larbouret, Marta Jarlier, Caroline Mollevi, Adeline Torro, Maguy Del Rio, Pierre Martineau and Céline Gongora
    Citation:BMC Cancer 2018 18:812
    Published on: 
  44. Content Type:Research Article

    The Musashi (MSI) family of RNA-binding proteins is best known for the role in post-transcriptional regulation of target mRNAs. Elevated MSI1 levels in a variety of human cancer are associated with up-regulati...
    Authors:Lan Lan, Hao Liu, Amber R. Smith, Carl Appelman, Jia Yu, Sarah Larsen, Rebecca T. Marquez, Xiaoqing Wu, Frank Y. Liu, Philip Gao, Ragul Gowthaman, John Karanicolas, Roberto N. De Guzman, Steven Rogers, Jeffrey Aubé, Kristi L. Neufeld…
    Citation:BMC Cancer 2018 18:809
    Published on: 
  45. Content Type:Research Article

    Sirtuin 2 (SIRT2) is a member of the sirtuin family, nicotinamide adenine dinucleotide+-dependent deacylases, which participates in modulation of cell cycle control, neurodegeneration, and tumorigenesis. SIRT2 ex...
    Authors:Tomohiro Kozako, Paolo Mellini, Takeo Ohsugi, Akiyoshi Aikawa, Yu-ichiro Uchida, Shin-ichiro Honda and Takayoshi Suzuki
    Citation:BMC Cancer 2018 18:791
    Published on: 
  46. Content Type:Research Article

    Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene...
    Authors:Kyriakos P. Papadopoulos, Eytan Ben-Ami, Amita Patnaik, Denise Trone, Jianke Li and George D. Demetri
    Citation:BMC Cancer 2018 18:790
    Published on: 
  47. Content Type:Research Article

    Disulfiram (DS), an antialcoholism medicine, demonstrated strong anticancer activity in the laboratory but did not show promising results in clinical trials. The anticancer activity of DS is copper dependent. ...
    Authors:Kate Butcher, Vinodh Kannappan, Rajagopal Sharada Kilari, Mark R. Morris, Christopher McConville, Angel L. Armesilla and Weiguang Wang
    Citation:BMC Cancer 2018 18:753
    Published on: 

No hay comentarios:

Publicar un comentario